UBS Group’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

UBS Group’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-1,000	Closed	-$9K	–	8099
2015 Q4	$9K	Hold	1,000	–	–	﹤0.01%	7366
2015 Q3	$6K	Hold	1,000	–	–	﹤0.01%	7613
2015 Q2	$11K	Hold	1,000	–	–	﹤0.01%	7401
2015 Q1	$16K	Sell	1,000 -39,400	-98%	-$610K	﹤0.01%	7220
2014 Q4	$614K	Buy	+40,400	New	+$491K	﹤0.01%	4010

Other funds holding SGMO

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

AIM

Axiom Investment Management New York $150M AUM

FTUS

Flow Traders U.S. New York $2.43B AUM 44.44% 1-Year Est. Return

HIG

Heritage Investment Group Pompano Beach, Florida $744M AUM 20.51% 1-Year Est. Return

UBS Group's SGMO Position: Q2 2026 in Review

UBS Group sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2026, closing a stake of 2,570,992 shares — an estimated $635K sold.

UBS Group first reported a position in SGMO in Q4 2014 and held it in 46 quarters. The position peaked at $4.33M in Q1 2021. 6 funds tracked by Wall St. Rank hold SGMO as of Q2 2026.

UBS Group reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2026 after selling out during the quarter.
UBS Group sold 2,570,992 SANGAMO THERAPEUTICS INC shares in Q2 2026, an estimated $635K.
UBS Group first reported a position in SANGAMO THERAPEUTICS INC in Q4 2014 and held it in 46 quarters.
UBS Group's SANGAMO THERAPEUTICS INC position peaked at $4.33M in Q1 2021.
6 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.